By Adriano Marchese

Quest Diagnostics raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter.

The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion.

Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share.

In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago.

Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share.

Revenue rose 15% to $2.76 billion, which includes 5.2% growth from organic revenues, beating expectations of a rise to $2.73 billion.

Chairman and Chief Executive Jim Davis said the company benefited from demand for clinical solutions and expanded business from enterprise accounts that complemented growth from acquisitions.

"We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance," Davis said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

July 22, 2025 07:33 ET (11:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.